Actively Recruiting
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
Led by Deciphera Pharmaceuticals, LLC · Updated on 2026-05-05
24
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.
CONDITIONS
Official Title
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female participants aged 18 to 55 years
- In good general health as determined by the study doctor
- Body mass index (BMI) between 18.5 and 30 kg/m²
- Adequate organ function based on blood and urine tests as required by the study
You will not qualify if you...
- History or presence of significant diseases affecting the neurological, skin, kidney, liver, gastrointestinal, heart, musculoskeletal, psychiatric, immune, endocrine, or metabolic systems
- Unwilling or unable to follow the study requirements
- Considered unsuitable for participation by the study doctor for any other reason
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nucleus Network
Saint Paul, Minnesota, United States, 55114
Actively Recruiting
Research Team
C
Clinical Team
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here